ITMN pulls Actimmune, revenue guidance

InterMune (ITMN) pulled its full year guidance for Actimmune interferon gamma-1b after first quarter sales of the drug came in below "internal expectations." In the first quarter, Actimmune sales were $32.9 million, down 13% from $37.9 million in the same period last year. The company said the rate of patient referrals in the first quarter was "significantly" lower than expected. However, ITMN said that the average duration of Actimmune therapy was higher than expected. Actimmune is approved for chronic granulomatous disease and severe malignant osteopetrosis and is used off label for idiopathic pulmonary fibrosis (IPF). ...